Stammdaten
BeOne Medicines, ehemals bekannt als BeiGene, ist ein weltweit tätiges Onkologieunternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung innovativer Krebstherapien konzentriert. Das 2010 gegründete und in Cambridge, Massachusetts ansässige Unternehmen mit Operationen in über 45 Ländern auf sechs Kontinenten wurde Ende 2024 in BeOne umbenannt und verlegte 2025 seinen Sitz nach Basel, Schweiz. BeOne hat sich als führender Anbieter in der Immuno-Onkologie und gezielten Therapien etabliert, mit Schlüsselprodukten einschließlich Tevimbra (tislelizumab), einem weltweit für mehrere Krebsindikationen zugelassenen PD-1-monoklonalen Antikörper, und Brukinsa (zanubrutinib), einem Bruton-Tyrosinkinase-(BTK-)Hemmer, der 1,3 Milliarden Dollar in jährlichen Verkäufen überschritten hat und in großen Märkten wie den USA, Europa und China zugelassen ist. Die Unternehmensstrategie kombiniert interne Forschung und Entwicklung mit der Entwicklung von Vermögenswerten aus externen Partnerschaften und treibt eine robuste Pipeline über hämatologische Malignome und solide Tumore. KI
Unternehmen & Branche
| Name | BeOne Medicines Ltd. |
|---|---|
| Ticker | ONC |
| CIK | 0001651308 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 07725L102 |
|---|---|
| ISIN | US07725L1026 |
| Typ | ADR |
| Marktkapitalisierung | 469,65 Mrd. USD |
| KGV (P/E) | 1.715,26 |
| Beta | 0,48 |
Sitz & Kontakt
| Geschäftsadresse | C/O BEONE MEDICINES I GMBH AESCHENGRABEN 27, 21ST FLOOR, 4051 BASEL |
|---|---|
| Telefon | 41-616851900 |
| EIN (IRS) | 98-1209416 |
Listing & Historie
| Listing-Börsen | Nasdaq · OTC |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | BeiGene, Ltd. (bis 2025) |
Bewertung
| KBV (P/B) | 107,69 vs. 58,97 (2021) ▲ |
|---|---|
| KUV (P/S) | 87,90 vs. 307,44 (2021) ▼ |
| EV/EBITDA | 791,8 |
| FCF-Rendite | 0,2 % vs. -0,4 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 87,5 % vs. 86,0 % (2021) ▲ |
|---|---|
| Operative Marge | 8,4 % vs. -122,3 % (2021) ▲ |
| Nettomarge | 5,4 % vs. -123,9 % (2021) ▲ |
| ROIC | 5,3 % vs. -21,4 % (2021) ▲ |
| Nettoverschuldung/EBITDA | -5,9 |
| Zinsdeckungsgrad | 7,7 vs. -49,2 (2021) ▲ |
| Forderungslaufzeit (DSO) | 59 T vs. 150 T (2021) ▼ |
| Lagerreichweite (DIO) | 332 T vs. 537 T (2021) ▼ |
| Verbindlichkeitslaufzeit (DPO) | 262 T vs. 581 T (2021) ▼ |
| Cash-Conversion-Cycle (CCC) | 130 T vs. 106 T (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 58,97 | 68,05 | 69,32 | 76,90 | 100,39 | 98,66 | |
| KUV (P/S) | 307,44 | 210,65 | 99,73 | 67,26 | 81,94 | 81,83 | |
| EV/EBITDA | – | – | – | – | 737,7 | 557,5 | |
| FCF-Rendite | -0,4 % | -0,6 % | -0,7 % | -0,2 % | 0,2 % | 0,2 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 86,0 % | 79,8 % | 84,5 % | 84,4 % | 87,5 % | 88,3 % | |
| Operative Marge | -122,3 % | -126,4 % | -49,1 % | -14,9 % | 8,4 % | 12,0 % | |
| Nettomarge | -123,9 % | -141,5 % | -35,9 % | -16,9 % | 5,4 % | 8,9 % | |
| ROIC | -21,4 % | -40,2 % | -19,7 % | -14,6 % | 5,3 % | 8,7 % | |
| Nettoverschuldung/EBITDA | – | – | – | – | -5,9 | -4,3 | |
| Zinsdeckungsgrad | -49,2 | -82,5 | -276,7 | -26,1 | 7,7 | 8,2 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ONC
BeOne Medicines Ltd.
Effektiv
Neutral
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
30,5
40 neu, 109 erhöht, 296,8M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 292.35 | +11.5 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 314.21 | +3.7 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 72 Tagen @ 305.64 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 309.04 | EMA50: 300.15 | |
| MACD-Histogramm | Bullisch | 10 % | 1.823 | Bullisch | |
| RSI(14) | Neutral | 10 % | 69.5 | Neutral (30–70) | |
| Stoch %K(14) | Bärisch | 5 % | 84.4 | Überkauft | |
| ADX(14)+DI | Bullisch | 10 % | 30.3 | +DI: 31.7 / −DI: 14.2 | |
| Z-Score(60) | Bärisch | 5 % | 1.67 | Extrem überkauft | |
| 52W-Position | Neutral | 5 % | 56.0 % | Hoch 377.47 / Tief 260.27 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 87.4 % | Upper 331.89 / Mid 308.21 / Lower 284.53 | |
| LinReg-Slope(60) | Neutral | 10 % | +0.1513 | R²=0.02 / annualisiert +12.9 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-22 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -1.669 | 325,00 | -542.425,00 | -33,7% | |
| 2026-07-21 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -20.029 | 316,91 | -6.347.340,32 | -394,9% | |
| 2026-07-21 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -7.842 | 318,41 | -2.496.997,10 | -155,4% | |
| 2026-07-21 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -2.340 | 320,06 | -748.936,42 | -46,6% | |
| 2026-07-21 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -15.379 | 316,26 | -4.863.765,62 | -302,6% | |
| 2026-07-21 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -15.807 | 319,29 | -5.047.018,61 | -314,0% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.850 | 313,91 | -580.731,65 | -36,1% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.512 | 315,26 | -476.677,66 | -29,7% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -280 | 318,30 | -89.124,00 | -5,5% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -523 | 316,14 | -165.339,28 | -10,3% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -15.499 | 312,29 | -4.840.114,51 | -301,1% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -14.326 | 312,96 | -4.483.433,44 | -278,9% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6.273 | 310,75 | -1.949.310,29 | -121,3% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5.146 | 310,08 | -1.595.677,86 | -99,3% | |
| 2026-07-20 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -2.907 | 311,80 | -906.388,65 | -56,4% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.440 | 305,20 | -439.485,84 | -27,3% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -35.829 | 312,17 | -11.184.910,91 | -695,9% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -14.915 | 313,19 | -4.671.197,53 | -290,6% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5.543 | 311,42 | -1.726.217,69 | -107,4% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4.833 | 310,37 | -1.500.015,31 | -93,3% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -740 | 314,32 | -232.596,65 | -14,5% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -680 | 309,05 | -210.156,79 | -13,1% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -597 | 306,96 | -183.257,63 | -11,4% | |
| 2026-07-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -51 | 315,06 | -16.068,18 | -1,0% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -233 | 311,98 | -72.691,34 | -4,5% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -42.798 | 317,79 | -13.600.720,78 | -846,2% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -32.224 | 316,82 | -10.209.120,68 | -635,2% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -20.505 | 321,00 | -6.582.063,99 | -409,5% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -19.752 | 316,00 | -6.241.632,00 | -388,3% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -15.097 | 319,99 | -4.830.934,32 | -300,6% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -13.109 | 321,61 | -4.216.020,88 | -262,3% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -9.516 | 314,73 | -2.994.987,81 | -186,3% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6.402 | 318,55 | -2.039.352,62 | -126,9% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4.881 | 314,08 | -1.533.010,81 | -95,4% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.560 | 322,71 | -503.423,86 | -31,3% | |
| 2026-07-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -520 | 323,59 | -168.264,62 | -10,5% | |
| 2026-07-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -12.857 | 311,71 | -4.007.685,04 | -249,3% | |
| 2026-07-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6.067 | 310,02 | -1.880.891,95 | -117,0% | |
| 2026-07-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -48.657 | 312,86 | -15.222.746,30 | -947,1% | |
| 2026-07-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -41.336 | 310,92 | -12.852.304,86 | -799,6% | |
| 2026-07-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -7.640 | 313,58 | -2.395.745,85 | -149,1% | |
| 2026-07-14 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4.139 | 303,07 | -1.254.401,35 | -78,0% | |
| 2026-07-14 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -45.895 | 306,21 | -14.053.627,28 | -874,4% | |
| 2026-07-14 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -40.781 | 306,93 | -12.517.112,16 | -778,8% | |
| 2026-07-14 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -39.090 | 305,02 | -11.923.259,16 | -741,8% | |
| 2026-07-14 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -8.122 | 303,93 | -2.468.490,22 | -153,6% | |
| 2026-07-14 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -7.834 | 307,57 | -2.409.533,93 | -149,9% | |
| 2026-07-13 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -26.294 | 303,83 | -7.988.777,18 | -497,0% | |
| 2026-07-13 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -8.438 | 304,68 | -2.570.892,37 | -160,0% | |
| 2026-07-13 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -7.240 | 306,82 | -2.221.409,38 | -138,2% | |
| 2026-07-13 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4.584 | 302,79 | -1.387.980,65 | -86,4% | |
| 2026-07-13 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -846 | 305,57 | -258.508,33 | -16,1% | |
| 2026-07-13 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -798 | 301,94 | -240.945,25 | -15,0% | |
| 2026-07-13 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -320 | 307,41 | -98.369,60 | -6,1% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -136 | 302,19 | -41.097,99 | -2,6% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -18 | 303,03 | -5.454,54 | -0,3% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5.143 | 298,94 | -1.537.428,88 | -95,7% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -3.074 | 298,35 | -917.132,82 | -57,1% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.493 | 296,07 | -442.028,33 | -27,5% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.314 | 297,23 | -390.560,61 | -24,3% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -370 | 300,12 | -111.044,36 | -6,9% | |
| 2026-07-10 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -150 | 301,18 | -45.177,42 | -2,8% | |
| 2026-07-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 302,46 | -200.833,44 | -12,5% | |
| 2026-06-23 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -320 | 275,10 | -88.030,40 | -5,5% | |
| 2026-06-23 | Wang Lai | Officer, President, Global Head of R&D | Open Market Sale | -1.068 | 276,74 | -295.552,98 | -18,4% | |
| 2026-06-23 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.800 | 273,30 | -491.948,82 | -30,6% | |
| 2026-06-23 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.290 | 274,12 | -353.612,99 | -22,0% | |
| 2026-06-23 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -1.292 | 276,26 | -356.926,89 | -22,2% | |
| 2026-06-16 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -590 | 265,98 | -156.925,25 | -9,8% | |
| 2026-06-16 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -1.357 | 266,76 | -361.996,85 | -22,5% | |
| 2026-06-16 | Wang Lai | Officer, President, Global Head of R&D | Open Market Sale | -1.169 | 265,39 | -310.235,88 | -19,3% | |
| 2026-06-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.710 | 265,99 | -454.835,38 | -28,3% | |
| 2026-06-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.650 | 264,87 | -437.041,77 | -27,2% | |
| 2026-06-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -333 | 266,69 | -88.809,34 | -5,5% | |
| 2026-06-11 | Ball Titus B. | Officer, Principal Accounting Officer | Open Market Sale | -49 | 256,39 | -12.562,96 | -0,8% | |
| 2026-06-11 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -859 | 257,59 | -221.271,10 | -13,8% | |
| 2026-06-11 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -741 | 256,23 | -189.865,10 | -11,8% | |
| 2026-06-11 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 258,28 | -51.655,84 | -3,2% | |
| 2026-06-11 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -149 | 258,81 | -38.562,69 | -2,4% | |
| 2026-06-11 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -428 | 257,64 | -110.267,78 | -6,9% | |
| 2026-06-11 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -626 | 261,20 | -163.512,26 | -10,2% | |
| 2026-06-11 | Rosenberg Aaron | Officer, Chief Financial Officer | Open Market Sale | -631 | 257,74 | -162.636,53 | -10,1% | |
| 2026-06-11 | Wang Lai | Officer, President, Global Head of R&D | Open Market Sale | -756 | 261,00 | -197.317,59 | -12,3% | |
| 2026-06-11 | Ball Titus B. | Officer, Principal Accounting Officer | Open Market Sale | -120 | 257,53 | -30.903,60 | -1,9% | |
| 2026-06-08 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.120 | 271,14 | -303.678,03 | -18,9% | |
| 2026-06-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -711 | 270,24 | -192.137,94 | -12,0% | |
| 2026-06-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -160 | 271,26 | -43.401,20 | -2,7% | |
| 2026-06-08 | Ball Titus B. | Officer, Principal Accounting Officer | Open Market Sale | -100 | 271,06 | -27.105,76 | -1,7% | |
| 2026-06-08 | Ball Titus B. | Officer, Principal Accounting Officer | Open Market Sale | -36 | 272,08 | -9.794,88 | -0,6% | |
| 2026-06-08 | Wang Lai | Officer, President, Global Head of R&D | Open Market Sale | -1.327 | 269,34 | -357.417,63 | -22,2% | |
| 2026-06-08 | Wang Lai | Officer, President, Global Head of R&D | Open Market Sale | -40 | 270,73 | -10.829,20 | -0,7% | |
| 2026-06-08 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -40 | 270,55 | -10.822,00 | -0,7% | |
| 2026-06-08 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -1.444 | 269,33 | -388.916,13 | -24,2% | |
| 2026-06-08 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -3.820 | 270,38 | -1.032.869,55 | -64,3% | |
| 2026-06-01 | Yi Qingqing | Director | Open Market Sale | -235 | 279,13 | -65.595,55 | -4,1% | |
| 2026-05-22 | BAKER BROS. ADVISORS LP | Director | Open Market Sale | -2.756 | 23,79 | -65.566,62 | -4,1% | |
| 2026-05-22 | Riva Alessandro | Director | Open Market Sale | -212 | 309,51 | -65.617,01 | -4,1% | |
| 2026-05-22 | Dugan Margaret | Director | Open Market Sale | -212 | 309,60 | -65.635,56 | -4,1% | |
| 2026-05-22 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -212 | 309,59 | -65.633,00 | -4,1% | |
| 2026-05-22 | BAKER BROS. ADVISORS LP | Director | Open Market Sale | -2.743 | 23,85 | -65.423,84 | -4,1% | |
| 2026-05-13 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 310,72 | -103.159,04 | -6,4% | |
| 2026-04-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 311,59 | -103.447,88 | -6,4% | |
| 2026-03-11 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -341 | 300,00 | -102.300,00 | -6,4% | |
| 2026-02-04 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -996 | 350,00 | -348.600,00 | -21,7% | |
| 2026-02-04 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 348,79 | -231.596,56 | -14,4% | |
| 2026-01-07 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 331,76 | -220.288,64 | -13,7% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.973 | 304,36 | -600.507,41 | -37,4% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.877 | 300,80 | -564.596,53 | -35,1% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.633 | 303,13 | -495.012,60 | -30,8% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.512 | 302,31 | -457.096,80 | -28,4% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.255 | 304,13 | -381.684,66 | -23,7% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -40 | 305,24 | -12.209,60 | -0,8% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -600 | 300,98 | -180.586,26 | -11,2% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -7.470 | 302,74 | -2.261.491,70 | -140,7% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5.442 | 303,72 | -1.652.854,58 | -102,8% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -2.567 | 301,79 | -774.699,29 | -48,2% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -929 | 313,52 | -291.256,09 | -18,1% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -16.318 | 310,48 | -5.066.489,33 | -315,2% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -14.163 | 308,41 | -4.368.017,91 | -271,8% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -10.650 | 309,37 | -3.294.797,96 | -205,0% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6.389 | 302,29 | -1.931.330,81 | -120,2% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5.829 | 304,37 | -1.774.160,49 | -110,4% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5.118 | 307,38 | -1.573.167,77 | -97,9% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4.949 | 306,39 | -1.516.335,00 | -94,3% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -3.940 | 305,55 | -1.203.866,61 | -74,9% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -2.344 | 311,33 | -729.749,08 | -45,4% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.896 | 303,60 | -575.628,82 | -35,8% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.791 | 301,58 | -540.126,74 | -33,6% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1.194 | 314,92 | -376.009,35 | -23,4% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -121 | 311,93 | -37.743,45 | -2,3% | |
| 2025-12-11 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 325,00 | -107.900,00 | -6,7% | |
| 2025-12-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 318,28 | -105.668,96 | -6,6% | |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -1.823 | 340,20 | -620.185,33 | -38,6% | |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -804 | 342,47 | -275.349,10 | -17,1% | |
| 2025-11-17 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -826 | 381,19 | -314.862,20 | -19,6% | |
| 2025-11-17 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -3.155 | 380,23 | -1.199.617,45 | -74,6% | |
| 2025-11-17 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -10 | 382,32 | -3.823,20 | -0,2% | |
| 2025-11-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -4.240 | 380,33 | -1.612.582,66 | -100,3% | |
| 2025-11-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -1.769 | 381,05 | -674.076,92 | -41,9% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -500 | 350,44 | -175.220,50 | -10,9% | |
| 2025-11-12 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 348,75 | -231.570,00 | -14,4% | |
| 2025-11-12 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 350,00 | -116.200,00 | -7,2% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -4.846 | 360,10 | -1.745.024,25 | -108,6% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -3.240 | 351,41 | -1.138.569,05 | -70,8% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -789 | 352,78 | -278.341,29 | -17,3% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -251 | 354,20 | -88.903,30 | -5,5% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -154 | 362,07 | -55.759,07 | -3,5% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -120 | 355,00 | -42.600,00 | -2,7% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -100 | 357,43 | -35.743,18 | -2,2% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -4.733 | 350,22 | -1.657.580,37 | -103,1% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -4.162 | 351,12 | -1.461.374,76 | -90,9% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -1.112 | 350,00 | -389.200,00 | -24,2% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 347,82 | -230.952,48 | -14,4% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -400 | 327,78 | -131.112,00 | -8,2% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4.008 | 326,90 | -1.310.226,82 | -81,5% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -12.446 | 326,14 | -4.059.091,15 | -252,5% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6.883 | 325,06 | -2.237.401,75 | -139,2% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4.066 | 324,12 | -1.317.862,16 | -82,0% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -300 | 326,80 | -98.040,00 | -6,1% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -4.776 | 325,19 | -1.553.123,68 | -96,6% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -3.318 | 325,73 | -1.080.760,20 | -67,2% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -1.112 | 325,00 | -361.400,00 | -22,5% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -500 | 327,93 | -163.965,00 | -10,2% | |
| 2025-09-09 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -5.000 | 350,06 | -1.750.311,50 | -108,9% | |
| 2025-09-05 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -2.665 | 337,00 | -898.105,00 | -55,9% | |
| 2025-09-02 | Ball Titus B. | Officer, Principal Accounting Officer | Open Market Sale | -122 | 326,76 | -39.864,72 | -2,5% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -600 | 308,03 | -184.819,32 | -11,5% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -12.232 | 306,26 | -3.746.189,44 | -233,1% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -8.522 | 305,48 | -2.603.297,15 | -162,0% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -6.965 | 303,31 | -2.112.586,19 | -131,4% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -5.800 | 302,04 | -1.751.856,94 | -109,0% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -4.917 | 307,43 | -1.511.625,93 | -94,0% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -500 | 304,19 | -152.097,45 | -9,5% | |
| 2025-08-14 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -400 | 300,86 | -120.345,48 | -7,5% | |
| 2025-08-13 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -3.849 | 301,00 | -1.158.552,85 | -72,1% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -3.517 | 303,54 | -1.067.564,25 | -66,4% | |
| 2025-08-13 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -1.112 | 300,00 | -333.600,00 | -20,8% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -528 | 305,59 | -161.352,26 | -10,0% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -9.637 | 306,74 | -2.956.093,86 | -183,9% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -9.617 | 307,38 | -2.956.061,92 | -183,9% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -8.900 | 300,33 | -2.672.961,92 | -166,3% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -7.359 | 304,37 | -2.239.886,79 | -139,4% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -5.800 | 302,45 | -1.754.193,76 | -109,1% | |
| 2025-08-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -4.500 | 301,49 | -1.356.702,75 | -84,4% | |
| 2025-08-13 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -6.052 | 300,19 | -1.816.724,46 | -113,0% | |
| 2025-08-01 | Rosenberg Aaron | Officer, Chief Financial Officer | Open Market Sale | -1.190 | 290,47 | -345.659,30 | -21,5% | |
| 2025-07-30 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -920 | 304,60 | -280.232,74 | -17,4% | |
| 2025-07-30 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -259 | 305,00 | -78.995,00 | -4,9% | |
| 2025-07-29 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -2.949 | 302,00 | -890.595,94 | -55,4% | |
| 2025-07-29 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -800 | 304,16 | -243.330,40 | -15,1% | |
| 2025-07-29 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -292 | 302,92 | -88.454,07 | -5,5% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 8.799.053 | 0 | 8.799.053 | 2.613.054.769 | Neu | +100,0% | |
| PRIMECAP MANAGEMENT CO/CA/ | 4.975.181 | 0 | 4.975.181 | 1.477.479.502 | Neu | +100,0% | |
| Capital International Investors | 4.158.726 | 0 | 4.158.726 | 1.231.236.530 | Neu | +100,0% | |
| FMR LLC | 3.693.610 | 0 | 3.693.610 | 1.096.891.494 | Neu | +100,0% | |
| Capital World Investors | 1.622.687 | 0 | 1.622.687 | 481.889.358 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.052.498 | 0 | 1.052.498 | 312.560.331 | Neu | +100,0% | |
| HHLR ADVISORS, LTD. | 1.034.306 | 0 | 1.034.306 | 307.157.853 | Neu | +100,0% | |
| Temasek Holdings (Private) Ltd | 862.643 | 0 | 862.643 | 256.179.092 | Neu | +100,0% | |
| BlackRock, Inc. | 657.501 | 0 | 657.501 | 195.258.096 | Neu | +100,0% | |
| Siren, L.L.C. | 465.000 | 0 | 465.000 | 138.091.050 | Neu | +100,0% | |
| MORGAN STANLEY | 464.472 | 0 | 464.472 | 137.934.923 | Neu | +100,0% | |
| UBS Group AG | 415.330 | 0 | 415.330 | 123.340.550 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 405.273 | 0 | 405.273 | 120.353.804 | Neu | +100,0% | |
| Baird Financial Group, Inc. | 349.651 | 0 | 349.651 | 103.836.007 | Neu | +100,0% | |
| Capital International, Inc./CA/ | 302.243 | 0 | 302.243 | 89.757.104 | Neu | +100,0% | |
| Candriam S.C.A. | 259.731 | 0 | 259.731 | 77.132.315 | Neu | +100,0% | |
| Man Group plc | 241.922 | 0 | 241.922 | 71.843.576 | Neu | +100,0% | |
| FIRST TRUST ADVISORS LP | 241.426 | 0 | 241.426 | 71.696.279 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 204.846 | 0 | 204.846 | 60.833.117 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 201.641 | 0 | 201.641 | 59.881.349 | Neu | +100,0% | |
| Nuveen, LLC | 196.429 | 0 | 196.429 | 58.333.520 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 184.356 | 0 | 184.356 | 54.748.201 | Neu | +100,0% | |
| Capital International Sarl | 173.879 | 0 | 173.879 | 51.636.847 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 172.643 | 0 | 172.643 | 51.269.793 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 155.002 | 0 | 155.002 | 46.030.944 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 154.465 | 0 | 154.465 | 45.871.471 | Neu | +100,0% | |
| M&G Plc | 138.163 | 0 | 138.163 | 41.034.411 | Neu | +100,0% | |
| Artisan Partners Limited Partnership | 137.216 | 0 | 137.216 | 40.749.036 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 119.608 | 0 | 119.608 | 35.519.988 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 110.586 | 0 | 110.586 | 32.840.724 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 109.553 | 0 | 109.553 | 32.533.954 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 96.677 | 0 | 96.677 | 28.710.299 | Neu | +100,0% | |
| Patient Square Capital LP | 80.542 | 0 | 80.542 | 23.918.558 | Neu | +100,0% | |
| CAPITAL INTERNATIONAL LTD /CA/ | 76.515 | 0 | 76.515 | 22.722.660 | Neu | +100,0% | |
| Squarepoint Ops LLC | 74.124 | 0 | 74.124 | 22.012.604 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 70.391 | 0 | 70.391 | 20.905.000 | Neu | +100,0% | |
| BARCLAYS PLC | 66.122 | 0 | 66.122 | 19.636.252 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 65.456 | 0 | 65.456 | 19.438.468 | Neu | +100,0% | |
| LAZARD ASSET MANAGEMENT LLC | 62.917 | 0 | 62.917 | 18.684.461 | Neu | +100,0% | |
| ABN AMRO INVESTMENT SOLUTIONS | 65.524 | 47.564 | 17.960 | 18.672.374 | Aufgestockt | +37,8% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 7.815 | 0 | 7.815 | 17.874.746 | Neu | +100,0% | |
| Legal & General Group Plc | 59.812 | 0 | 59.812 | 17.776.027 | Neu | +100,0% | |
| ENVESTNET ASSET MANAGEMENT INC | 59.611 | 0 | 59.611 | 17.702.778 | Neu | +100,0% | |
| PANAGORA ASSET MANAGEMENT INC | 57.320 | 0 | 57.320 | 17.022.320 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 56.879 | 0 | 56.879 | 16.859.037 | Neu | +100,0% | |
| SEB Asset Management AB | 56.078 | 0 | 56.078 | 16.653.463 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 52.063 | 0 | 52.063 | 15.461.149 | Neu | +100,0% | |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 49.344 | 0 | 49.344 | 14.017.644 | Neu | +100,0% | |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 43.430 | 0 | 43.430 | 12.897.407 | Neu | +100,0% | |
| BARINGS LLC | 42.815 | 0 | 42.815 | 12.714.771 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| ABN AMRO INVESTMENT SOLUTIONS | 65.524 | 47.564 | +37,8% | 18.672.374 | 24,47 | 100 % | 14 Q |
| Atle Fund Management AB | 35.180 | 41.717 | -15,7% | 10.025.244 | 13,14 | 100 % | 7 Q |
| Mirae Asset Global Investments Co., Ltd. | 33.808 | 23.740 | +42,4% | 9.634.266 | 12,63 | 100 % | 12 Q |
| Slow Capital, Inc. | 28.237 | 28.492 | -0,9% | 8.046.698 | 10,55 | 100 % | 6 Q |
| Asset Management One Co., Ltd. | 21.346 | 21.346 | 0,0% | 6.082.970 | 7,97 | 100 % | 17 Q |
| Erste Asset Management GmbH | 20.100 | 21.900 | -8,2% | 5.828.799 | 7,64 | 100 % | 17 Q |
| Crossmark Global Holdings, Inc. | 10.755 | 7.661 | +40,4% | 3.064.852 | 4,02 | 100 % | 17 Q |
| China Universal Asset Management Co., Ltd. | 5.257 | 5.672 | -7,3% | 1.498.087 | 1,96 | 100 % | 16 Q |
| WESPAC Advisors SoCal, LLC | 5.082 | 4.925 | +3,2% | 1.448.218 | 1,90 | 64 % | 4 Q |
| PEAK FINANCIAL ADVISORS LLC | 4.836 | 0 | +100,0% | 1.378.115 | 1,81 | 0 % | 1 Q |
| Charles Schwab Trust Co | 3.000 | 0 | +100,0% | 854.910 | 1,12 | 100 % | 1 Q |
| TD Waterhouse Canada Inc. | 1.975 | 2.032 | -2,8% | 573.318 | 0,75 | 100 % | 7 Q |
| QRG CAPITAL MANAGEMENT, INC. | 1.918 | 1.688 | +13,6% | 546.645 | 0,72 | 100 % | 6 Q |
| COMMONWEALTH EQUITY SERVICES, LLC | 1.825 | 1.759 | +3,8% | 519.956 | 0,68 | – | 4 Q |
| SBI Okasan Asset Management Co.Ltd. | 1.700 | 1.700 | 0,0% | 492.983 | 0,65 | 100 % | 3 Q |
| JGP Global Gestao de Recursos Ltda. | 1.711 | 1.711 | 0,0% | 487.584 | 0,64 | 100 % | 17 Q |
| Prasad Wealth Partners, LLC | 1.518 | 1.518 | 0,0% | 432.445 | 0,57 | 100 % | 4 Q |
| Alteri Wealth LLC | 1.500 | 1.500 | 0,0% | 427.455 | 0,56 | 100 % | 7 Q |
| Venturi Wealth Management, LLC | 1.481 | 1.477 | +0,3% | 422.042 | 0,55 | 2 % | 16 Q |
| PFG Investments, LLC | 1.455 | 1.455 | 0,0% | 414.631 | 0,54 | 0 % | 7 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 64 | 0,3 | 76 |
| 31.03.2026 | ✓ | 279 | 34,9 | 10.173 |
| 31.12.2025 | ✓ | 284 | 34,6 | 11.633 |
| 30.09.2025 | ✓ | 265 | 33,8 | 10.889 |
| 30.06.2025 | ✓ | 242 | 34,8 | 8.115 |
| 31.03.2025 | ✓ | 263 | 43,8 | 11.104 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Capital World Investors | 1.622.687 | 481.889.358 |
| JANE STREET GROUP, LLC | 75.953 | 22.555.762 |
| RENAISSANCE TECHNOLOGIES LLC | 65.456 | 19.438.468 |
| SEB Asset Management AB | 56.078 | 16.653.463 |
| Rokos Capital Management LLP | 14.335 | 4.255.846 |
| ADAR1 Capital Management, LLC | 11.701 | 3.474.846 |
| Banco Santander, S.A. | 4.469 | 1.327.159 |
| TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC | 4.439 | 1.318.250 |
| SANDERS MORRIS HARRIS LLC | 2.700 | 801.819 |
| Perigon Wealth Management, LLC | 2.537 | 753.413 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 1.032.298 | 498.781 | +93.5 % | 306.561.537 |
| UBS Group AG | 415.330 | 263.243 | +173.1 % | 123.340.550 |
| MILLENNIUM MANAGEMENT LLC | 204.846 | 173.395 | +551.3 % | 60.833.117 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 155.002 | 131.789 | +567.7 % | 46.030.944 |
| FIRST TRUST ADVISORS LP | 241.426 | 115.601 | +91.9 % | 71.696.279 |
| FRANKLIN RESOURCES INC | 201.641 | 107.047 | +113.2 % | 59.881.349 |
| JENNISON ASSOCIATES LLC | 154.465 | 78.027 | +102.1 % | 45.871.471 |
| Candriam S.C.A. | 259.731 | 62.470 | +31.7 % | 77.132.315 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 110.586 | 54.260 | +96.3 % | 32.840.724 |
| Baird Financial Group, Inc. | 349.651 | 45.312 | +14.9 % | 103.836.007 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Capital International Investors | 4.158.726 | -955.140 | -18.7 % | 1.231.236.530 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 539.769 | -832.910 | -60.7 % | 160.297 |
| FMR LLC | 3.693.610 | -299.017 | -7.5 % | 1.096.891.494 |
| Jain Global LLC | 1.668 | -95.667 | -98.3 % | 495.346 |
| Temasek Holdings (Private) Ltd | 862.643 | -56.944 | -6.2 % | 256.179.092 |
| GOLDMAN SACHS GROUP INC | 96.677 | -52.037 | -35.0 % | 28.710.299 |
| Siren, L.L.C. | 465.000 | -35.000 | -7.0 % | 138.091.050 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.614 | -34.925 | -95.6 % | 479.310 |
| DEUTSCHE BANK AG\ | 27.877 | -32.779 | -54.0 % | 8.278.633 |
| Artisan Partners Limited Partnership | 137.216 | -28.025 | -17.0 % | 40.749.036 |
Zusätzlich aktuell von 95 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 15.06.2026 | Baker Bros. Advisors (GP) LLC (+1) | Aktivist (13D/A) | 8,00 % | 115.457.154 | 0,00 pp | On June 11, 2026, Felix J. Baker, Ph.D., a managing member of the Adviser GP, was electe… | |
| 15.06.2026 | FBB3 LLC | Aktivist (13D/A) | 0,01 % | 144.517 | 0,00 pp | On June 11, 2026, Felix J. Baker, Ph.D., a managing member of the Adviser GP, was electe… | |
| 15.06.2026 | Julian C. Baker (+1) | Aktivist (13D/A) | 8,00 % | 115.912.814 | 0,00 pp | On June 11, 2026, Felix J. Baker, Ph.D., a managing member of the Adviser GP, was electe… | |
| 14.05.2026 | Capital International Investors | Passiv (13G/A) | 4,20 % | 65.211.266 | -1,60 pp | – | |
| 16.04.2026 | Julian C. Baker (+1) | Aktivist (13D/A) | 8,00 % | 115.918.313 | -1,00 pp | On April 16, 2026, the Issuer filed a Preliminary Proxy Statement disclosing that Felix … | |
| 16.04.2026 | Baker Bros. Advisors (GP) LLC (+1) | Aktivist (13D/A) | 8,00 % | 115.462.653 | -1,00 pp | On April 16, 2026, the Issuer filed a Preliminary Proxy Statement disclosing that Felix … | |
| 16.04.2026 | FBB3 LLC | Aktivist (13D/A) | 0,01 % | 144.517 | -0,09 pp | On April 16, 2026, the Issuer filed a Preliminary Proxy Statement disclosing that Felix … | |
| 13.05.2025 | Capital International Investors | Passiv (13G/A) | 5,80 % | 81.647.620 | Neu | – | |
| 13.05.2025 | Hillhouse Investment Management, Ltd. (+1) | Aktivist (13D/A) | 4,90 % | 68.551.141 | -1,80 pp | – | |
| 03.03.2025 | Hillhouse Investment Management, Ltd. (+1) | Aktivist (13D/A) | 6,70 % | 92.805.741 | -2,30 pp | – | |
| 10.12.2024 | FBB3 LLC | Aktivist (13D/A) | 0,10 % | 144.517 | 0,00 pp | – | |
| 10.12.2024 | Julian C. Baker (+1) | Aktivist (13D/A) | 9,00 % | 125.276.610 | -1,20 pp | – | |
| 10.12.2024 | Baker Bros. Advisors (GP) LLC (+1) | Aktivist (13D/A) | 9,00 % | 124.820.950 | -1,20 pp | – | |
| 04.12.2024 | Hillhouse Investment Management, Ltd. (+1) | Aktivist (13D/A) | 9,00 % | 125.045.741 | -1,90 pp | – | |
| 05.02.2024 | John V. Oyler | Passiv (13G/A) | 5,20 % | 71.464.808 | +0,10 pp | – | |
| 14.11.2023 | Baker Bros. Advisors (GP) LLC (+1) | Aktivist (13D/A) | 10,20 % | 138.222.377 | -1,00 pp | – | |
| 14.11.2023 | FBB3 LLC | Aktivist (13D/A) | 0,10 % | 144.517 | 0,00 pp | – | |
| 14.11.2023 | Julian C. Baker (+1) | Aktivist (13D/A) | 10,20 % | 138.678.037 | -1,00 pp | – | |
| 05.05.2023 | Baker Bros. Advisors (GP) LLC (+1) | Aktivist (13D/A) | 11,20 % | 152.522.377 | -1,80 pp | – | |
| 05.05.2023 | Julian C. Baker (+1) | Aktivist (13D/A) | 11,20 % | 152.978.037 | -1,80 pp | – | |
| 05.05.2023 | FBB3 LLC | Aktivist (13D/A) | 0,10 % | 144.517 | 0,00 pp | – | |
| 14.02.2023 | Hillhouse Investment Management, Ltd. (+1) | Aktivist (13D/A) | 10,90 % | 147.043.058 | 0,00 pp | – | |
| 10.02.2023 | John V. Oyler | Passiv (13G/A) | 5,10 % | 70.026.397 | 0,00 pp | – | |
| 10.02.2023 | Invesco Ltd. | Passiv (13G/A) | 2,60 % | 35.678.240 | -3,00 pp | – | |
| 16.08.2022 | Hillhouse Investment Management, Ltd. (+1) | Aktivist (13D/A) | 10,90 % | 147.035.258 | Neu | – | |
| 14.02.2022 | John V. Oyler | Passiv (13G/A) | 5,10 % | 69.558.605 | 0,00 pp | – | |
| 11.02.2022 | John V. Oyler | Passiv (13G/A) | 5,10 % | 69.558.605 | -0,90 pp | – | |
| 11.02.2022 | Invesco Ltd. | Passiv (13G) | 5,60 % | 39.028.821 | Neu | – |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | 227.357.000 $ | 0,15 $ | 8.553.619.000 $ | 4.760.442.000 $ |
| 2025-12-31 | 10-K | – | 286.933.000 $ | 0,19 $ | 8.188.573.000 $ | 4.361.194.000 $ |
| 2025-09-30 | 10-Q | – | 124.841.000 $ | 0,08 $ | 7.632.586.000 $ | 4.129.326.000 $ |
| 2025-06-30 | 10-Q | – | 94.320.000 $ | 0,06 $ | 6.298.394.000 $ | 3.770.475.000 $ |
| 2025-03-31 | 10-Q | – | 1.270.000 $ | 0,00 $ | 5.841.526.000 $ | 3.499.513.000 $ |
| 2024-12-31 | 10-K | – | -644.786.000 $ | -0,47 $ | 5.920.910.000 $ | 3.332.222.000 $ |
| 2024-09-30 | 10-Q | – | -121.350.000 $ | -0,09 $ | 5.830.860.000 $ | 3.436.073.000 $ |
| 2024-06-30 | 10-Q | – | -120.405.000 $ | -0,09 $ | 5.712.179.000 $ | 3.366.255.000 $ |
| 2024-03-31 | 10-Q | – | -251.150.000 $ | -0,19 $ | 5.667.681.000 $ | 3.360.361.000 $ |
| 2023-12-31 | 10-K | – | -881.708.000 $ | -0,65 $ | 5.805.275.000 $ | 3.537.327.000 $ |
| 2023-09-30 | 10-Q | – | 215.413.000 $ | 0,15 $ | 5.524.879.000 $ | 3.763.234.000 $ |
| 2023-06-30 | 10-Q | – | -381.137.000 $ | -0,28 $ | 5.728.736.000 $ | 3.798.559.000 $ |
| 2023-03-31 | 10-Q | – | -348.431.000 $ | -0,26 $ | 5.956.775.000 $ | 4.157.306.000 $ |
| 2022-12-31 | 10-K | – | -2.003.815.000 $ | -1,49 $ | 6.379.290.000 $ | 4.383.355.000 $ |
| 2022-09-30 | 10-Q | – | -557.556.000 $ | -0,41 $ | 6.726.013.000 $ | 4.655.171.000 $ |
| 2022-06-30 | 10-Q | – | -565.726.000 $ | -0,42 $ | 7.378.207.000 $ | 5.196.919.000 $ |
| 2022-03-31 | 10-Q | – | -435.198.000 $ | -0,33 $ | 8.021.388.000 $ | 5.774.152.000 $ |
| 2021-12-31 | 10-K | – | -1.457.816.000 $ | -1,21 $ | 8.535.525.000 $ | 6.132.563.000 $ |
| 2021-09-30 | 10-Q | – | -438.114.000 $ | -0,36 $ | 5.286.334.000 $ | 3.357.073.000 $ |
| 2021-06-30 | 10-Q | – | -480.341.000 $ | -0,40 $ | 5.524.116.000 $ | 3.606.775.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 5,3 Mrd. | 3,8 Mrd. | 2,2 Mrd. | 1,3 Mrd. | 634,0 Mio. | 98,9 % | +39,8% | |
| Collaboration | 61,0 Mio. | 30,7 Mio. | 268,9 Mio. | 161,3 Mio. | 542,3 Mio. | 1,1 % | +98,6% | |
| Right To Access Intellectual Property Revenue | – | – | – | 105,0 Mio. | 4,0 Mio. | – | – | |
| Collaboration Research And Development Service | – | – | – | 46,8 Mio. | 53,7 Mio. | – | – | |
| Collaboration Other | – | – | – | 9,5 Mio. | – | – | – | |
| License | – | – | – | – | 484,6 Mio. | – | – |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Product | 1,4 Mrd. | 1,3 Mrd. | 1,1 Mrd. | 993,4 Mio. | 921,1 Mio. | 746,9 Mio. | 98,8 % | +40,4% | |
| Other Revenue | 17,3 Mio. | – | – | – | – | – | 1,2 % | Neu | |
| Collaboration | – | 13,2 Mio. | 8,7 Mio. | 8,2 Mio. | 8,0 Mio. | 4,7 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 2,9 Mrd. | 2,0 Mrd. | 1,1 Mrd. | 502,6 Mio. | 495,3 Mio. | 53,9 % | +47,1% | |
| CN | 1,7 Mrd. | 1,4 Mrd. | 1,1 Mrd. | 840,0 Mio. | 517,2 Mio. | 31,4 % | +19,0% | |
| Europe | 611,4 Mio. | 362,6 Mio. | 202,0 Mio. | – | – | 11,4 % | +68,6% | |
| All Other Countries Except China United States Of America And Switzerland | 171,8 Mio. | – | – | – | – | 3,2 % | Neu | |
| All Other Countries Except China And United States Of America | – | 78,8 Mio. | 26,6 Mio. | 73,3 Mio. | 163,8 Mio. | – | – |
Quartalsverlauf
| Region | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| US | 754,9 Mio. | 694,4 Mio. | 567,2 Mio. | 505,5 Mio. | 481,4 Mio. | 351,5 Mio. | 53,4 % | +49,3% | |
| CN | 439,9 Mio. | 432,9 Mio. | 399,6 Mio. | 376,0 Mio. | 352,1 Mio. | 320,4 Mio. | 31,1 % | +17,0% | |
| Europe | 166,6 Mio. | 152,4 Mio. | 118,6 Mio. | 98,3 Mio. | 82,4 Mio. | 66,9 Mio. | 11,8 % | +69,5% | |
| All Other Countries Except China And United States Of America | 51,0 Mio. | 35,6 Mio. | 31,9 Mio. | 21,9 Mio. | 13,3 Mio. | 13,0 Mio. | 3,6 % | +132,9% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 06.05.2026 | 1,5 Mrd. USD | 0,15 |
| Q3 2025 | 30.09.2025 | 06.11.2025 | 1,4 Mrd. USD | 0,08 |
| Q2 2025 | 30.06.2025 | 06.08.2025 | 1,3 Mrd. USD | 0,06 |
| Q1 2025 | 31.03.2025 | 07.05.2025 | 1,1 Mrd. USD | 0,00 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | 1,0 Mrd. USD | -0,09 |
| Q2 2024 | 30.06.2024 | 07.08.2024 | 929,2 Mio. USD | -0,09 |
| Q1 2024 | 31.03.2024 | 08.05.2024 | 751,7 Mio. USD | -0,19 |
| Q3 2023 | 30.09.2023 | 09.11.2023 | 781,3 Mio. USD | 0,15 |
| Q2 2023 | 30.06.2023 | 02.08.2023 | 595,3 Mio. USD | -0,28 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 06.05.2026 | 10-Q | 31.03.2026 | 36 Tage | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 06.11.2025 | 10-Q | 30.09.2025 | 37 Tage | SEC » |
| 06.08.2025 | 10-Q | 30.06.2025 | 37 Tage | SEC » |
| 07.05.2025 | 10-Q | 31.03.2025 | 37 Tage | SEC » |
| 28.02.2025 | 10-K/A | 31.12.2024 | 59 Tage | SEC » |
| 27.02.2025 | 10-K | 31.12.2024 | 58 Tage | SEC » |
| 08.01.2025 | 10-K/A | 31.12.2023 | 374 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 07.08.2024 | 10-Q | 30.06.2024 | 38 Tage | SEC » |
| 08.05.2024 | 10-Q | 31.03.2024 | 38 Tage | SEC » |
| 26.02.2024 | 10-K | 31.12.2023 | 57 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 02.08.2023 | 10-Q | 30.06.2023 | 33 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 27.02.2023 | 10-K | 31.12.2022 | 58 Tage | SEC » |
| 09.11.2022 | 10-Q | 30.09.2022 | 40 Tage | SEC » |
| 08.08.2022 | 10-Q | 30.06.2022 | 39 Tage | SEC » |
| 09.05.2022 | 10-Q | 31.03.2022 | 39 Tage | SEC » |
| 28.02.2022 | 10-K | 31.12.2021 | 59 Tage | SEC » |
| 04.11.2021 | 10-Q | 30.09.2021 | 35 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 25.02.2021 | 10-K | 31.12.2020 | 56 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 06.08.2020 | 10-Q | 30.06.2020 | 37 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 01.12.2021 | Kapitalerhöhung | $3,99 Mrd | SEC » |
| 23.11.2021 | Kapitalerhöhung | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 28.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2026 | HV-Einladung | 11.06.2026 Jahres-HV | 22.05.2026 | DEF 14A | SEC » |
| 16.04.2026 | Vorläufig | — | — | PRE 14A | SEC » |
| 07.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 07.04.2025 | HV-Einladung | 21.05.2025 Jahres-HV | 26.03.2025 | DEF 14A | SEC » |
| 27.03.2025 | Vorläufig | — | — | PRE 14A | SEC » |
| 10.03.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 26.04.2024 | HV-Einladung | 05.06.2024 Jahres-HV | 19.04.2024 | DEF 14A | SEC » |
| 15.04.2024 | Vorläufig | — | — | PRE 14A | SEC » |
| 27.04.2023 | HV-Einladung | 15.06.2023 Jahres-HV | 17.04.2023 | DEF 14A | SEC » |
| 17.04.2023 | Vorläufig | — | — | PRE 14A | SEC » |
| 29.04.2022 | HV-Einladung | 22.06.2022 Jahres-HV | 18.04.2022 | DEF 14A | SEC » |
| 18.04.2022 | Vorläufig | — | — | PRE 14A | SEC » |
| 30.04.2021 | HV-Einladung | — | — | DEF 14A | SEC » |
| 19.04.2021 | Vorläufig | — | — | PRE 14A | SEC » |
| 29.01.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 09.10.2020 | HV-Einladung | 20.11.2020 a.o. HV | — | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 28.02.2025 | Fusion | S-4/A | Ziel: BeiGene, Ltd. | SEC » |
| 21.01.2025 | Fusion | S-4/A | Ziel: BeiGene, Ltd. | SEC » |
| 07.08.2024 | Fusion | S-4 | Ziel: BeiGene, Ltd. | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (11.06.2026)
HOCH Abgang Schlüsselpersonen (11.06.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 11.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 26.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 20.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 22.06.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 03.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.02.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.07.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 30.03.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 03.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.11.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 25.08.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.06.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.01.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 26.06.2026 | Behördliche Maßnahme | -0,25 | 40 | BeOne ist Gegenstand laufender Steueraudits außerhalb der USA mit potenziellen erheblichen Abweichungen in den geschätzten Haftungen. Die An… 🔒 | SEC |
| 11.06.2026 | Personalwechsel | 0,00 | 55 | Auf der Jahreshauptversammlung vom 11. Juni 2026 wurden Änderungen in der Geschäftsleitung bestätigt, die zuvor im Proxy-Statement vom 28. A… 🔒 | SEC |
| 15.05.2026 | Behördliche Maßnahme | 0,80 | 82 | BeOne Medicines gab die FDA-Zulassung von BEQALZI™ (Sonrotoclax) mit beschleunigtem Verfahren für die Behandlung von refraktärem Mantelzelll… 🔒 | SEC |
| 06.05.2026 | Quartalszahlen | 0,00 | 50 | BeOne Medicines gab Finanzergebnisse für Q1 2026 ab. Keine Hinweise auf Beat/Miss in den verfügbaren Auszügen. | SEC |
| 14.04.2026 | Sonstiges | 0,00 | 15 | BeOne Medicines reicht 2025 Jahresbericht bei der Shanghai Stock Exchange ein. Routine-Compliance-Meldung für den chinesischen Listungsmarkt… 🔒 | SEC |
| 26.02.2026 | Quartalszahlen | 0,00 | 60 | BeOne Medicines kündigte die Finanzergebnisse für Q4 und Volljahreszeitraum 2025 an. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 421 | 289,99 | 122.086 |
| 2026-06-29 | 244 | 279,89 | 68.293 |
| 2026-06-11 | 18 | 263,61 | 4.745 |
| 2026-05-28 | 585 | 300,01 | 175.506 |
| 2026-05-21 | 1.274 | 308,74 | 393.335 |
| 2026-05-14 | 665 | 316,55 | 210.506 |
| 2026-05-05 | 304 | 297,14 | 90.331 |
| 2026-05-04 | 304 | 293,86 | 89.333 |
| 2026-04-20 | 99 | 323,87 | 32.063 |
| 2026-04-16 | 10.000 | 319,94 | 3.199.400 |
| 2026-03-24 | 298 | 274,73 | 81.870 |
| 2026-03-20 | 1 | 282,72 | 283 |
| 2026-03-13 | 2.864 | 285,30 | 817.099 |
| 2026-03-12 | 148 | 298,91 | 44.239 |
| 2026-03-11 | 3.585 | 305,39 | 1.094.823 |
| 2026-03-05 | 3 | 299,02 | 897 |
| 2026-02-27 | 796 | 322,37 | 256.607 |
| 2026-02-26 | 1.576 | 352,23 | 555.114 |
| 2026-02-25 | 357 | 369,00 | 131.733 |
| 2026-02-23 | 296 | 362,14 | 107.193 |
| 2026-02-19 | 54 | 359,05 | 19.389 |
| 2026-02-18 | 363 | 354,86 | 128.814 |
| 2026-02-09 | 14.246 | 353,92 | 5.041.944 |
| 2026-02-06 | 299 | 347,00 | 103.753 |
| 2026-02-04 | 6 | 346,38 | 2.078 |
| 2026-02-03 | 15.045 | 345,00 | 5.190.525 |
| 2026-01-30 | 21 | 350,00 | 7.350 |